Liraglutide to Improve corONary Haemodynamics During Exercise streSS

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1 receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress testing, in those patients with reversible myocardial ischaemia and obstructive coronary artery disease confirmed by a baseline exercise test and coronary angiography respectively.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King's College London
• Collaborator: Guy's and St Thomas' NHS Foundation Trust
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

1. Men and women aged 18-80

2. Patients with a recent abnormal exercise tolerance test demonstrating >0.1 mV of planar or down-sloping ST-segment depression.

3. Patients with known coronary artery disease and angiographic evidence of a >70% stenosis in a main epicardial artery, with or without coronary stenoses elsewhere.

4. Patients must be able to walk confidently on a treadmill.

5. Patients must have a normal resting electrocardiogram (ECG) in sinus rhythm without bundle branch aberration or other conduction disturbance.

6. Patients must have normal left ventricular function.

Exclusion Criteria:

1. An abnormal resting ECG including atrial fibrillation, bundle branch aberration or other conduction disturbance.

2. Pre-existing left ventricular systolic dysfunction.

3. Pre-existing ischaemic or non-ischaemic cardiomyopathy.

4. Pre-existing valvular heart disease.

5. Inability to safely negotiate an exercise treadmill.

6. Type I diabetes mellitus.

7. Type II diabetes mellitus taking oral or subcutaneous anti diabetic therapy.